Kexing Biopharm Co., Ltd. (SHA:688136)
China · Delayed Price · Currency is CNY 20.78
-0.39 (-1.84%)
Sep 2, 2026, 3:00 PM CST
Kexing Biopharm Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 4,189 | 6,274 | 4,323 | 4,034 | 4,260 | 5,617 | |
Market Cap Growth | -52.29% | 45.13% | 7.17% | -5.31% | -24.16% | -30.78% |
Enterprise Value | 5,038 | 7,062 | 5,012 | 4,566 | 4,301 | 5,203 |
Last Close Price | 21.17 | 31.26 | 21.54 | 19.95 | 21.13 | 27.76 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 20.01 | 40.33 | 137.32 | - | - | 58.23 |
Forward PE | 34.15 | 38.04 | 41.58 | - | - | - |
PS Ratio | 2.91 | 4.09 | 3.07 | 3.20 | 3.24 | 4.37 |
PB Ratio | 2.28 | 3.58 | 2.64 | 2.47 | 2.36 | 2.94 |
P/TBV Ratio | 2.58 | 4.12 | 3.07 | 2.75 | 2.59 | 2.98 |
P/FCF Ratio | - | 2611.79 | 340.98 | - | - | - |
P/OCF Ratio | 51.41 | 72.93 | 40.53 | - | - | 59.75 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.50 | 4.60 | 3.56 | 3.63 | 3.27 | 4.05 |
EV/EBITDA Ratio | 73.56 | 38.36 | 26.89 | - | - | 67.21 |
EV/EBIT Ratio | - | 80.17 | 50.87 | - | - | 123.25 |
EV/FCF Ratio | - | 2939.59 | 395.29 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.79 | 0.80 | 0.75 | 0.68 | 0.57 | 0.32 |
Debt / EBITDA Ratio | 21.30 | 7.16 | 6.12 | - | - | 6.53 |
Debt / FCF Ratio | - | 581.45 | 96.29 | - | - | - |
Net Debt / Equity Ratio | 0.46 | 0.43 | 0.41 | 0.34 | 0.14 | -0.14 |
Net Debt / EBITDA Ratio | 13.55 | 4.05 | 3.57 | -3.26 | -3.60 | -3.57 |
Net Debt / FCF Ratio | -95.38 | 310.68 | 52.55 | -1.97 | -0.52 | 0.99 |
Asset Turnover | 0.41 | 0.46 | 0.45 | 0.41 | 0.44 | 0.50 |
Inventory Turnover | 4.43 | 4.02 | 2.67 | 1.85 | 1.71 | 1.86 |
Quick Ratio | 1.14 | 1.38 | 1.29 | 1.37 | 2.18 | 2.09 |
Current Ratio | 1.35 | 1.57 | 1.45 | 1.69 | 2.62 | 2.42 |
Return on Equity (ROE) | 11.71% | 9.01% | 1.65% | -11.38% | -5.00% | 5.16% |
Return on Assets (ROA) | -0.66% | 1.64% | 1.99% | -4.86% | -2.61% | 1.02% |
Return on Invested Capital (ROIC) | -1.28% | 3.38% | 2.09% | -11.36% | -6.79% | 3.15% |
Return on Capital Employed (ROCE) | -1.40% | 3.50% | 4.30% | -10.20% | -4.80% | 1.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 4.99% | 2.48% | 0.73% | -4.72% | -2.12% | 1.72% |
FCF Yield | -0.21% | 0.04% | 0.29% | -6.90% | -11.39% | -4.95% |
Dividend Yield | 1.22% | 0.80% | 0.37% | - | - | 0.36% |
Payout Ratio | 43.79% | 36.89% | 138.60% | - | - | 29.43% |
Buyback Yield / Dilution | -0.03% | -0.08% | 0.74% | 1.21% | -1.93% | -31.59% |
Total Shareholder Return | 1.19% | 0.72% | 1.11% | 1.21% | -1.93% | -31.23% |